Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings makes new appointments

An alternate director and chief medical advisor have been appointed.
AusCann Group Holdings makes new appointments
Shares are 75% above their February listing price

AusCann Group Holdings (ASX:AC8) has appointed a new alternate director to its board and new chief medical advisor to its staff.

Bruce Linton, a non-executive director has appointed David Pryce to act as his alternate director effective from today.

Pryce is currently vice president of international market expansion and global government relations at Canopy Growth Corp., the largest cannabinoid medicine producer in North America.

In this capacity, Pryce is responsible for taking the company into new markets, growing footprint and driving its global expansion.

Elaine Darby, managing director, commented: “We have worked with David for some time on a management level and the board will greatly benefit from his experience given our international expansion objectives.

“These objectives include expansion into the South American market with our existing Chilean operation and investigating international opportunities with our strategic partner Tasmanian Alkaloids.”


Chief medical advisor

International medical cannabis expert, Dr Danial Schecter has been appointed chief medical advisor.

Doctor training and awareness forms a key part of the company’s strategy to educate the medical community on the potential benefits of cannabinoids as therapeutic agents to treat certain conditions, such as chronic pain.

Schecter believes Australian physicians have not been taught about the endocannabinoid system in medical school or post-graduate training and there are no formal learning pathways.

Because of this, a potentially valuable medication is not going to be prescribed to a large portion of the population who could significantly benefit from this.

In order to rectify this situation, to allow patients access to cannabinoid medicines, Schecter believes it is crucial to support medical education





Register here to be notified of future AC8 Company articles
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

researcher using microscope
September 29 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use